Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis

NCT02039505 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

292

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: Vedolizumab
DRUG: Vedolizumab placebo

Sponsor

Takeda